Close
Novotech
Jabsco PureFlo 21 Single Use

Stellar Biotechnologies develops aquaculture system for KLH manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.
- Advertisement -

Stellar Biotechnologies has developed a controlled, commercial-scale aquaculture system for fully sustainable Keyhole Limpet Hemocyanin (KLH) manufacturing.

The land-based aquaculture system is designed to support multiple generations of all stages of Megathura crenulata’s life cycle, producing pharmaceutical grade KLH in commercial scale.

Stellar president and CEO Frank Oakes said, “This is about controlling the lifecycle of the source animal, allowing Stellar to grow new generations of limpets spawned by parents that have never seen the ocean, thus ensuring that the pharmaceutical industry has ample supply of GMP grade KLH, made under controlled conditions, while protecting survival of a wild species.”

The great keyhole limpet is the common name of mollusk Megathura crenulata, which is KLH’s marine source.

Stellar aquaculture manager Brandon Lincucum said, “We’ve set the benchmark for KLH manufacturing and we’re proud to represent these new aquaculture and environmental milestones as well.”

Latest stories

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.

Early Insights Reduce Risk in Drug Development Programs

Leveraging early-stage data and translational research allows pharmaceutical companies to mitigate drug development risk and implement adaptive strategies for higher success.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »